Latest News about BIIB
Recent news which mentions BIIB
Should You Blame Biogen for Medicare Part B Premium Hikes?
December 03, 2021
Tickers
BIIB
From Motley Fool
Sage Therapeutics - Biogen Share One Year Zuranolone 50mg Data In Depression Patients
December 01, 2021
From Benzinga
From Benzinga
Biogen Loses Bid To Revive Tecfidera Drug Patent: Bloomberg
November 30, 2021
From Benzinga
Could Roche Put a Crinkle in Biogen's Alzheimer's Drug Launch?
November 28, 2021
From Motley Fool
2 Moonshot Biotechs with 10x Potential
November 22, 2021
From InvestorPlace
The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
November 21, 2021
From Benzinga
1 Cancer Stock on Buyout Watch in 2022
November 21, 2021
From Motley Fool
Ocugen Stock: Bull vs. Bear
November 20, 2021
From Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
November 19, 2021
From Benzinga
From Benzinga
3 Biotech Stocks That Have More Than Tripled so far This Year
November 18, 2021
From Motley Fool
European Regulator Votes Down Biogen's Alzheimer's Drug
November 17, 2021
Tickers
BIIB
From Benzinga
Jim Cramer Likes This Stock Over Cassava Sciences And Biogen
November 17, 2021
From Benzinga
Could Eli Lilly Leapfrog Biogen in This Market?
November 17, 2021
From Motley Fool
The Daily Biotech Pulse: Kezar Jumps On Data, Biogen R&D Chief To Retire, Molecular Partners Wilts On COVID Trial Disappointment
November 16, 2021
From Benzinga
President Biden Nominates Robert Califf As New FDA Commissioner: Report
November 12, 2021
From Benzinga
Why Are Biogen Shares Gaining Today?
November 12, 2021
From Benzinga
The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares
November 12, 2021
From Benzinga
Eisai Posts New Lecanemab Data From Mid-Stage Alzheimer's Trial
November 11, 2021
From Benzinga
Is Compass Pathways Stock a Once-in-a-Lifetime Bargain?
November 11, 2021
From Motley Fool
The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts
November 11, 2021
From Benzinga
3 Vaccine Stocks With Big Opportunities Outside of COVID-19
November 11, 2021
From Motley Fool
Hit By Slow Rollout, Biogen's Aduhelm Could Soon Find Itself In Price Competition: Reuters
November 10, 2021
From Benzinga
This Company Says Its New Topical Therapy Trials Bringing Hope to People Exposed to Biofilm Bacteria
November 09, 2021
From Benzinga
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
November 09, 2021
From Benzinga